CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 21, 2009-- CombinatoRx, Incorporated (NASDAQ: CRXX) today announced the results of a 12 month knee osteoarthritis (OA) Phase 2 extension trial for Synavive TM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback